Trial Designs and Outcomes in Dementia Therapeutic Research
Auteurs : Rockwood Kenneth, Gauthier Serge
Given the increased attention by clinicians, researchers and the pharmaceutical industry to the management and treatment of dementia not only in the elderly but also in increasingly younger populations, the demands for effective evidence-based pharmaceutical control of dementia and quantitative assessment of outcomes have increased. Since some first steps in the early 1960's to the controversial landmark paper of Summers and colleagues, to the most recent trials, it is clear both that much progress has been made, and that much remains to be done. This book is written to take stock of what is now usefully known, and to speculate on directions for the future.
Short Contents
Introduction. The History of Therapeutic Trials in Dementia. Therapeutic Strategies. Treatment Hypotheses. Clinical Trial Designs & Selection of Primary vs.Secondary Endpoints. Qualitative Analyses of Disease Treatment Effects. Inclusion and Exclusion Criteria. Global Outcomes. Cognitive Outcomes. Functional Outcomes. Behavioral Outcomes In Trials Of Cognitive Agents. Quality of Life Outcomes. Caregiver Burden Outcomes. Neuroimaging Outcomes. Additional Lessons From Trials in Vascular Dementia. Additional Lessons From Trials In Dementia With Lewy Bodies. Lessons From Trials To Prevent Dementia. Herbal Treatments for Dementia. Lessons from Trials of Psychoactive Compounds in Alzheimer's Disease. Lessons from Non-Pharmacologic and Psychosocial Interventions for Patients with Dementia. Lessons from Psychosocial Interventions Aimed at Caregivers of People with Dementia. Lessons from Trials in Mild Cognitive Impairment. Pharmacoeconomic Outcomes. Executive Dysfunction in Dementia. Ethical Issues. Conclusions.
Date de parution : 11-2005
Ouvrage de 300 p.
18.9x24.6 cm
Thèmes de Trial Designs and Outcomes in Dementia Therapeutic Research :
Mots-clés :
mild; alzheimer's; clinical; disease; cholinesterase; inhibitors; rating; cognitive; impairment; vascular; ADAS; ChEI; Alzheimer's Disease; ADCS; VaD; NINDS AIREN Criterion; Gas; BPSD Symptom; Vascular Cognitive Impairment; Parkinson's Disease Dementia; Lewy Bodies; Alzheimer's Disease Cooperative Study; DLB; Placebo Controlled Trials; Amnestic MCI; Probable VaD; DLB Patient; NINCDS ADRDA Criterion; Institutional Review Boards; IRBs; Clinical Practice; Moderate Severe Ad; MMSE Score; Dementia Trials; BPSD